Ken Geles

Ken Geles is a Tumor and Immune-Targeted Therapeutics Group Leader with over 14 years of experience in the pharmaceutical industry.

His expertise lies in developing next-generation oncology therapies like small molecules, biotherapeutics, nanoparticles, and antibody drug conjugate (ADC) programs from target identification to clinical testing.

Ken is skilled in managing large matrixed teams focused on oncology drug development, in vivo pharmacology, biomarkers, translational research, PK/PD, toxicology, due diligence, regulatory document preparation, patent applications, and peer-reviewed manuscripts.

His interests in drug discovery revolve around the discovery and validation of oncogenic driver mutations and the development of advanced organoid and 3D tumor microenvironment (TME) culture models for screening cancer therapies.

Ken Geles' specialties include anti-cancer agents, small molecules, antibodies, biotherapeutics, ADCs, nanoparticles, immunotherapy, tumor immunology, cancer stem cells, developmental signaling pathways, Notch signaling, and target ID through clinical testing.